ArticleCardiology research2026
Prevention of Cardiovascular Disease and Cancer Through Early Statin Treatment in Advanced Atherosclerosis: An Observational Study.
Article in Cardiology research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The extent of atherosclerosis in healthy men and women was measured using ultrasound on the carotid artery, and it was investigated whether early treatment with statins in subjects with advanced atherosclerosis improves the outcome for cardiovascular disease and cancer. Method: From 2009 to 2017, 5,186 subjects (39.1% women) aged 35-65 with no signs of cardiovascular disease underwent ultrasound examination of the carotid artery. The total plaque area (TPA) and maximum plaque thickness were measured. Results: A follow-up was available for 4,340 (83.7%) participants. The mean follow-up period was 87 months (7.3 years) for men and 79 months (6.6 years) for women. Advanced atherosclerosis (type III, IVb) was present in 506 (11.7%) subjects. Statin treatment was initiated in 186 (36.8%) of the subjects. Events (heart attack, ischemic stroke, coronary artery bypass grafting (CABG), percutaneous transluminal coronary angioplasty (PTCA)) occurred in 170 (3.9%) of the 4,340 subjects with follow-up data. Cancer occurred in 71 (1.7%) of the subjects. The event rate for cardiovascular events was 37.6% in men with advanced atherosclerosis without statin therapy vs. 1.6% (P < 0.0001) in those with low-to-moderate plaque burden; for cancer, the rates were 8.6% vs. 1.2% (P < 0.0001). In women with advanced atherosclerosis, the event rate for cardiovascular events without statin therapy was 14.8% vs. 0.2% (P < 0.0001) in those with low-to-moderate plaque burden; and for cancer, the rates were 7.4% vs. 0.9% (P = 0.002). Treatment of male subjects with advanced atherosclerosis (type III, IVb) with a statin significantly improved the prognosis. The event rate for cardiovascular events was 16.1% in men in the treated group vs. 37.6% (P < 0.0001) in the untreated group, and 2.7% vs. 14.8% (P = 0.077) in women. The event rate for cancer was 2% in men in the treated group vs. 8.6% (P = 0.006) in the untreated group. Due to the low number of cases in women, a statistical evaluation did not make sense. Mortality (from any cause) was significantly lower in men treated with statins (P = 0.008). Conclusions: Treatment with statins in subjects with advanced atherosclerosis of the carotid artery (type III, IVb findings on ultrasound) significantly improved the prognosis in a non-randomized observational study.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.